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Rac1 Inhibition Prevents Tissue Contraction and MMP
Mediated Matrix Remodeling in the Conjunctiva
Victoria E. Tovell,1 Chi Y. Chau,1 Peng T. Khaw,2 and Maryse Bailly1
PURPOSE. To evaluate the efficiency of Rac1 inhibition in
preventing matrix contraction by Tenon’s capsule fibro-
blasts.
METHODS. The involvement of Rac1 in serum-stimulated matrix
contraction by human Tenon’s fibroblasts (HTFs) was investi-
gated in a classic collagen contraction model and our ex vivo
model of tissue contraction using immunocytochemistry,
chemical inhibitors, and small interfering RNA (siRNA)
technology. Matrix integrity was assessed using confocal
reflection microscopy and Coomassie blue staining. Quantita-
tive real-time polymerase chain reaction (QRT-PCR) and
Western blot analysis were used to assess matrix metal-
loproteinase (MMP) expression.
RESULTS. Serum induced Rac1 activation in HTF-populated
collagen gels and stimulated HTFs to contract collagen
matrices down to ~90% of their original size. Rac1 inhibition
using NSC23766 or depletion using siRNA both significantly
reduced HTF-mediated contraction. Early brief exposure to
NSC23766 reduced HTF-mediated gel contraction by 70%,
while transient treatment with the Rac1 inhibitor once a week
decreased ex vivo tissue contraction down to serum-free levels.
Transient exposure to NSC23766 prevented early cell protru-
sions, fiber alignment, and matrix degradation, as seen upon
continuous exposure to broad-spectrum MMP inhibitor.
However, unlike MMP inhibition, transient treatment with
NSC23766 led to a significant reduction in MMP1 mRNA and
protein expression during contraction, without increasing
MMP2 and MMP14 expression.
CONCLUSIONS. Rac1 inhibition efficiently prevents conjunctival
tissue and collagen matrix contraction and prevents matrix
degradation. (Invest Ophthalmol Vis Sci. 2012;53:4682–4691)
DOI:10.1167/iovs.11-8577
Contractile scarring following surgery or disease processesis still a major clinical challenge causing considerable
morbidity. The successful outcome of glaucoma filtration
surgery (GFS) is dependent upon the prevention of contractile
scarring at the surgical site. Fibroblasts from the Tenon’s
capsule are known to play a key role in contractile scarring
following GFS, or in diseases such as mucous membrane
pemphigoid, by remodeling the extracellular matrix (ECM).
However, signaling events that regulate matrix contraction and
remodeling during wound healing are poorly understood, and
the current treatment used to counteract the scarring process,
Mitomycin C (MMC), can lead to cell cytotoxicity and severe
side effects.1–3 Therefore, safer anti-scarring strategies, which
target contraction directly, would improve clinical outcomes.
The benefits of understanding the interplay between cellular
signaling events and ECM remodeling during fibroblast
contraction and wound healing would be very significant for
ocular scarring, and also for the many medical conditions
associated with contractile scarring.
Several studies have focused on MMP inhibition as a
potential anti-scarring strategy. MMPs are zinc-dependent
endopeptidases responsible for cleaving ECM proteins and
are produced by a variety of cell types after injury.4–11 MMPs
can be divided into sub-families depending on their catalytic
activity or whether they are membrane bound or not. Such
families include collagenases, gelatinases, and membrane-type
MMPs (MT-MMP), each of which is responsible for cleaving
different types of ECM proteins. A number of MMPs are
associated with the GFS wound site and scarring in vivo,12
which is consistent with evidence of matrix degradation and
remodeling.12,13 We have shown previously that collagen
degradation and matrix remodeling are an essential part of
the contraction process, both in a classic in vitro model of
fibroblast-mediated collagen matrix contraction14 and in a
recently developed ex vivo model of intact conjunctiva
contraction.13 In accordance with these studies,13,14 the
broad-range MMP inhibitor, GM6001, has been shown to
successfully inhibit HTF-mediated contraction in vitro and
postoperative scarring after experimental GFS.15–17 However,
the efficiency of the inhibitor is currently dependent on
continuous exposure to the drug, which can trigger a reactive
overexpression of some MMPs by the cells14,18 and may
complicate its use in clinical applications.
Contracting fibroblasts reorganize their cytoskeletal com-
ponents to generate a tensile strength, which is essential for
their role in postoperative scarring.19 Small Rho GTPases are
involved in regulating cytoskeletal organization, the most
studied of which are Cdc42, Rac, and Rho. While Rho
activation primarily stimulates stress fiber formation and focal
adhesions, Cdc42 and Rac stimulate the formation of filopodia
and lamellipodia, respectively. The role of Rho GTPases in actin
dynamics is well documented, and it has long been understood
that Rac1 can induce plasma membrane protrusions by
activating actin polymerization.20–22 Rac1 activity has been
shown to be essential for protrusive activity, tissue repair, and
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wound healing,23,24 and our own work has shown that
protrusive activity is an essential component of early matrix
contraction, suggesting that signaling through Rac1 could be
one major component of contractile scarring.14,25 However, so
far, no studies have looked into the role of Rac1 in Tenon’s
fibroblast-mediated matrix remodeling and contraction.
We thus sought to explore the potential of targeting the
small GTPase Rac1 to modulate tissue contraction and scarring
using both the in vitro collagen gel contraction model26–28 and
our ex vivo model of conjunctival contraction.13 Using both
model systems, we demonstrate here the effects of Rac1
inhibition on contraction and matrix remodeling. We reveal for
the first time a connection between Rac1 and MMP activity
during Tenon’s fibroblast contraction and show that transient
Rac1 inhibition is sufficient to significantly reduce matrix
contraction, degradation, and MMP1 expression.
METHODS
Cell Culture
HTFs were isolated from donor tissue in accordance with the tenets of
the Declaration of Helsinki and local ethics approval as previously
described.13 HTFs were routinely grown in Dulbecco’s modified Eagle’s
medium (DMEM) containing 2 mM L-glutamine, 100 U/mL penicillin,
and 100 lg/mL streptomycin, supplemented with 10% fetal bovine
serum (FBS). The following conditions were used throughout the
study: FBS (as above); granulocyte macrophage (GM) (FBSþ GM6001,
MMP inhibitor, 100 lM; Merck Chemicals Ltd., Nottingham, UK); NSC
(FBSþNSC23766, Rac1 inhibitor,29 50 lM for the first 24 hours; Tocris
Bioscience, Bristol, UK); and SMV (FBS þ simvastatin, small GTPase
inhibitor,30 10 lM; Enzo Life Sciences, Exeter, UK).
Collagen Gel and Ex Vivo Contraction Assays
The collagen contraction assays were performed as previously
described.13 Briefly, HTFs were seeded in a collagen type-I matrix
(First Link Ltd., Birmingham, UK) at a concentration of 50,000 cells/
mL. The gels were detached from the edge of the well, and 2 mL DMEM
was added containing the appropriate conditions. Digital photographs
were obtained daily over 7 days. Lattice areas were measured using
ImageJ software (in the public domain; http://rsb.info.nih.gov/ij/), and
contraction was expressed as a percentage of gel area normalized to
day 0. The ex vivo intact tissue contraction assay was performed as
previously described using porcine eyes.13
Microscopy and Quantification of Active
Rac1 Staining
Confocal reflection microscopy and live staining of cells in the
conjunctiva fragments were performed as previously described.13,14
Immunofluorescent staining was carried out by fixing the samples with
3.7% formaldehyde (Sigma, Poole, UK) followed by a 30-minute
FIGURE 1. Serum stimulates Rac1 activation during HTF-mediated gel contraction. (A) Cells seeded in collagen matrices were serum starved for 24
hours followed by either treatment with serum (FBS) or continued serum free (SF) for 24 hours. Cells were fixed and stained for F-actin and GTP-
Rac1, and fluorescence levels were measured on confocal sections using Image J. Results are mean 6 SEM for 3 experiments, with a total of 90 cells
per treatment; **P < 0.01. (B) Representative confocal Z-stack projection of HTFs stained for active Rac1 and F-actin. Scale bar, 30 lm. (C) Cells
seeded in collagen matrices were incubated with 10% FBS alone (FBS) or FBS in the presence of simvastatin (SMV, 10 lM) or Rac inhibitor NSC23766
(NSC, 5 or 10 lM). Gel contraction was monitored daily. Shown are mean 6 SEM for 3 experiments, each carried out in duplicate. (D)
Representative gel areas at day 7 in the presence of different inhibitors.
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incubation in 0.5% Triton-X100 (Sigma) and a 30-minute wash with 0.1
M glycine. Rhodamine-phalloidin (1:10; Invitrogen, Paisley, UK) was
added to the samples for 30 minutes before they were washed,
mounted, and viewed using a confocal laser scanning microscope
(Zeiss Axiovert S100/Biorad Radiance 2000; Zeiss, Cambridge, UK)
with a long-distance objective (LD Plan-NEOFLUAR, 63X/0.75 Korr;
Zeiss). To assess active Rac1 levels in HTFs, cells were serum starved
for 24 hours following gel polymerization, then treated with or without
serum (FBS or SF-FBS, respectively) for 24 hours. Rac1 activity in gels
was detected using anti-active (GTP)-Rac1 antibody (NewEast Biosci-
ences, King of Prussia, PA) and by following our routine immunoflu-
orescence protocol.14,31 Total GTP-Rac1 and F-actin levels were
quantitated as integrated density levels over the whole cell area in
ImageJ on 5-lm confocal slices taken within the central area of the
cells.31 To assess cell functionality following treatment with NSC23766,
HTF-populated collagen gels were incubated in medium with 10% FBS
and NSC23766 (50 lM, NSC-FBS) or in serum-free medium (SF-FBS) for
24 hours. The medium was replaced with fresh medium with 10% FBS
and the cells incubated for a further 24 hours, before being fixed and
stained for Rac-GTP. Control cells were kept in serum-free medium for
48 hours (SF:SF).
Measurement of Total Protein Content in Gels
Gels were fixed in 4% formaldehyde for 30 minutes then stained in
Coomassie blue for 30 minutes. The dye was extracted from the gels
with 70% ethanol for 1 hour, and samples were measured for their
absorbance at 550 nm (Fluostar Optima; BMG Biotech, Cary, NC).
LIVE/DEAD Cytotoxicity Assay
The viability of human Tenon’s fibroblasts was assessed following
exposure to various concentrations and application times of NSC23766
in collagen matrices. The LIVE/DEAD cytotoxicity assay (Invitrogen)
was used according to manufacturer’s instructions using 4 lM ethidium
homodimer-1 and 2 lM calcein AM; live cells (green) and dead cells
(red) were then visualized in gels using confocal microscopy on day 7
of the contraction assay. Z-stacks were acquired of five separate regions
per gel, and two-dimensional (2-D) projections of the merged red/green
images were used to count the percentage of live and dead cells.
Quantitative Real-Time PCR
Collagen gel contraction assays were ended at days 0, 1, 3, 5, and 7 by
placing the gels straight into TRIzol Reagent (Invitrogen). Control
mRNA levels at day 0 were obtained from cells in gels under serum-free
conditions and lysed in TRIzol within 15 minutes of initial gel
polymerization. Homogenization and phase separation were carried
out according to the TRIzol manufacturer’s instructions. The aqueous
phase was obtained and used for RNA isolation by the Qiagen column
method according to the standard protocol (RNeasy Mini Kit; Qiagen,
Valencia, CA). Reverse transcription was carried out using the
QuantiTect Reverse Transcription Kit (Qiagen) according to manufac-
turer’s instructions. MMP gene expression was measured by QRT-PCR
using validated primers and probes (Assay-on-Demand; Applied
Biosystems, Foster City, CA). Assay identification numbers are MMP1
( H s 0 0 8 9 9 6 5 8 _ m 1 ) , M M P 2 ( H s 0 1 5 4 8 7 2 7 _ m 1 ) , M M P 8
( H s 0 1 0 2 9 0 5 7 _ m 1 ) , M MP 9 ( H s 0 0 2 3 4 5 7 9 _ m 1 ) , M MP 1 3
(Hs00233992_m1), and MMP14 (Hs00237119_m1). The HPRT1 gene
was used as an endogenous control to normalize sample concentration.
RT-PCR reactions were performed on an HT7900 Fast Real-Time PCR
system (Applied Biosystems), and the delta analysis method32 was used
for quantification of mRNA levels.
Small Interfering RNA Transfection
Rac1 was knocked down using a mixture of four SMARTselection-
designed SiRNAs targeting human Rac1 (SiGENOME SMARTpool,
Darmacon) with the following target sequences: AUGAAAGUGU-
CACGGGUAA, CGGCACCACUGUCCCAACA, UAAAGACACGAUCGA-
GAAA, UAAGGAGAUUGGUGCUGUA. Cells were treated with 10 nM
Rac1 siRNA or control siRNA (SiGENOME Non-Targeting siRNA Pool
No. 2) for 72 hours using HiPerFect transfection reagent (Qiagen,
Lafayette, CO). Cells were then either lysed and used for Western
blotting of the Rac1 protein to determine downregulation efficiency or
trypsinized for the collagen gel contraction assay (as above).
Western Blot Analysis
Protein was extracted from gel samples following TRIzol manufactur-
er’s instructions. Equal amounts of protein were loaded onto and run
on 12% precast polyacrylamide mini-gels (Thermo Fisher Scientific,
Northumberland, UK) and then transferred, using a semi-dry transfer
system (Bio-Rad, Hercules, CA) onto polyvinylidene fluoride (PVDF)
membranes (Thermo Fisher Scientific). Membranes were blocked in 3%
reduced-fat milk powder in 0.05% Tween-20 in phosphate buffered
saline (TBS-T) followed by overnight incubation at 48C in primary
antibody (MMP1; 1:500, Abcam, Cambridge, UK or Rac1; 1:4000, BD
Transduction Laboratories, Oxford, UK). Membranes were washed 3
FIGURE 2. Transient treatment with the Rac1 inhibitor prevents
collagen matrix contraction by HTFs and ex vivo conjunctival
contraction. (A) HTF-mediated collagen gel contraction was inhibited
with a single 24-hour exposure with NSC23766 (50 lM; black arrow).
(B) Ex vivo segments of porcine conjunctiva were used to investigate
the effects of exposure to the Rac1 inhibitor in living tissue. Transient
treatment with NSC23766 (50 lM, for 24-hours, once a week, NSC
once/week [O/W]; arrowheads) reduced FBS-mediated contraction
levels down to the serum-free baseline (SF), whilst MMC (0.5 mg/mL,
for 2 minutes) obliterated ex vivo live tissue contraction. Results
shown are mean 6 SEM for n ¼ 3 experiments, each carried out in
triplicate.
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times for 10 minutes in TBS-T, incubated in secondary-labeled antibody
(IRDye 680, 1:5000; LI-COR, Cambridge, UK) for 2 hours at room
temperature, washed, and scanned on an Odyssey IR Imager (LI-COR).
RESULTS
Serum-Mediated Matrix Contraction Is Dependent
on Rac1 Activity
Active Rac1 amounts significantly increased in HTFs within
matrices following stimulation with 10% FBS (Figs. 1A, 1B),
whilst F-actin amounts remained the same. HTFs contracted
collagen matrices to approximately 90% of their original size
over 7 days in the presence of 10% FBS (Figs. 1C, 1D).
Inhibition of Rac1 activity by continuous exposure to the Rac1
inhibitor NSC23766 (NSC) or simvastatin (SMV) significantly
reduced matrix contraction by a minimum of 50%. Transient
treatment with the Rac1 inhibitor was also sufficient to prevent
matrix contraction by 70% in collagen gels and by 50% in our
ex vivo model of conjunctival contraction (Fig. 2). A single
exposure with NSC23766 (50 lM) for 24 hours almost fully
blocked fibroblast-mediated collagen gel contraction (Fig. 2A),
despite being nontoxic (Fig. 3A) and having no permanent
effect on the cells’ ability to activate Rac1 following serum
stimulation (Fig. 3B). Similarly, application of NSC23766 (50
lM) for 24 hours once a week reduced ex vivo tissue
contraction to the baseline serum-free level (Fig. 2B).
Nevertheless, a short exposure to MMC (Fig. 2B), equivalent
to the current modalities used during GFS,16 prevented even
baseline tissue contraction, owing to major cytotoxity.1–3
During GFS, a one-off treatment administrated directly to
the surgical site is highly desirable. Given the effectiveness of
the Rac1 inhibitor in preventing tissue and matrix contraction,
we attempted to determine whether shorter incubations with
higher concentrations could be as effective. Indeed, single
short treatments with high concentrations of NSC23766
efficiently inhibited contraction (Fig. 4). Treating cells with
200 lM NSC23766 for as little as 2 minutes was sufficient to
significantly reduce contraction by HTFs, even though no
toxicity was detected in concentrations up to 1 mM for a 30-
minute application.
To confirm the involvement of Rac1 in serum-mediated
matrix contraction, we specifically downregulated Rac1
expression in HTFs using siRNA. HTFs treated with Rac1
siRNA displayed reproducibly lower levels of Rac1 and
significantly reduced matrix contraction abilities compared
with cells treated with control siRNA (Fig. 5).
FIGURE 3. Transient treatment with Rac1 inhibitor is nontoxic. (A) HTFs were cast in collagen gels in the presence of 10% FBS and treated with
NSC23766 (50 lM, for 24 hours) or MMC (0.2 mg/mL, for 5 minutes). At day 7, a LIVE/DEAD viability assay was carried out. Live cells (green) and
dead cells (red) were then visualized using confocal microscopy and quantitated within five separate regions per gel. Results shown are mean 6
SEM for n¼ 3 experiments. Images show live cells in a control gel at day 7 and dead cells in a gel treated with ethanol to kill all the cells. Scale bar,
100 lm. (B) HTFs were cast in collagen gels in the presence of SF or NSC23766 (50 lM) for 24 hours. Media was then changed to FBS for stimulation
or maintained in SF for negative controls. Stimulation with FBS significantly (P < 0.05) increased GTP-bound Rac1 compared with SF controls even
following treatment with the Rac1 inhibitor. No significant difference was found between SF-pretreated cells and NSC-pretreated cells following
stimulation with serum. Results shown are mean 6 SEM for n ¼ 4 experiments (30 cells each).
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Inhibition of Rac1 Signaling Prevents Cell
Protrusions, Spreading, and Fiber Alignment
Tenon’s fibroblasts in collagen matrices in the presence of 10%
serum for 24 hours exhibited marked processes extending
from an elongated cell body (Figs. 6A, 6B). Inhibition of Rac1
altered cell spreading, with the cells exhibiting rounder cell
bodies and very fine protrusions, in a manner reminiscent of
that of cells in the presence of broad-spectrum MMP inhibitor
GM6001 (Fig. 6).14 In addition, both inhibitors prevented the
pericellular collagen fiber alignment that is normally observed
in the presence of serum,14 suggesting altered cell dynamics
(Fig. 6C).
Inhibition of Rac1 Signaling Prevents
Matrix Degradation
Since we showed previously that matrix degradation is an
essential component of matrix and tissue contraction,13 we
investigated whether Rac1 inhibition affected this process.
Both NSC23766 and GM6001 prevented collagen degradation
in HTF-populated matrices (Fig. 7A), as measured using
Coomassie blue uptake.13 Again, transient application of
NSC23766 (50 lM, first 24 hours) was sufficient to fully
prevent matrix degradation. This effect was confirmed by
confocal reflection microscopy of HTF-populated collagen
matrices. Both NSC23766 and GM6001 treatment prevented
degradation of collagen fibers that accompanies matrix
contraction after 7 days in the presence of 10% FBS (Fig. 7B).13
Using our ex vivo model of contraction, both tissue matrix
integrity and cell viability can be visualized in live conjunctiva
samples over a more physiologically relevant contraction time
course.13 As shown before, fresh conjunctival segments display
an abundant matrix, with a significant amount of intercalated
live resident cells (Fig. 8, t ¼ 0). Following 4 weeks of
contraction in the presence of 10% FBS, the collagen fibers are
almost completely degraded, though numerous viable cells are
seen within the samples (Fig. 8, t ¼ 28 FBS). Treatment with
MMC (0.2 mg/mL for 5 minutes) preserved fiber integrity but
was extremely cytotoxic, as no live cells were visible after 28
days. In contrast, NSC23766 did not appear to affect cell
viability, despite preventing matrix degradation as efficiently as
MMC (Fig. 8, NCS).
Transient Rac1 Inhibition Reduces
MMP1 Expression
Given the effects of the Rac1 inhibitor on matrix integrity, we
tested the effect of this inhibitor on MMP expression.
Collagenase mRNA expression (MMPs 1, 8, and 13) was
measured in contracting Tenon’s fibroblasts. MMP1 mRNA
levels were significantly increased following serum stimulation
compared with serum-free controls, starting at 24 hours after
stimulation and remaining elevated throughout the contraction
process (Fig. 9A). Expression of MMP 8 and 13 was
undetectable (data not shown). Continuous treatment with
GM6001 did not induce any change in MMP1 expression over
the 7 days in culture. However, MMP1 mRNA expression was
significantly reduced from day 5 following a single early
treatment with NSC 23766 (50 lM, first 24 hours), suggesting
that transient treatment with the Rac1 inhibitor is sufficient to
permanently alter MMP1 mRNA expression. This was con-
firmed at the protein level (Fig. 9B), showing a marked
decrease in MMP1 expression following transient treatment
with NSC23766.
The expression of other MMPs important for wound healing
was also investigated, specifically the gelatinases MMP2 and
MMP9, and the membrane-bound MMP14. No expression was
detectable for MMP9 (data not shown), and MMP2 and MMP14
expression, though significant, did not increase during the
contraction period (Fig. 10). GM6001 treatment led to a large
increase in MMP2, and particularly MMP14, expression, in
agreement with previous studies.14,18,33,34 On the contrary,
transient treatment with NSC23766 did not increase MMP2 or
MMP14 mRNA levels, with the exception of a slight increase on
day 7. These data suggest that targeting Rac1 may be a
potential treatment for postoperative scarring following GFS,
or disease, as it prevents matrix remodeling.
FIGURE 4. Short-term exposures of the Rac1 inhibitor at higher
concentrations prevent HTF-mediated contraction. Tenon’s fibroblasts
in collagen gels were exposed to NSC23766 at (A) 100 lM for 10, 30,
and 60 minutes or (B) 200 lM for 2, 5, and 10 minutes as soon as the
gels had polymerized and then maintained in 10% serum for 7 days. (C)
Cells in collagen gels were exposed to increasing concentrations of
NSC23766 (200, 300, 500, 1000, 3000 lM) for 30 minutes and
subjected to the Live/Dead assay at day 7 of the contraction assay.
Significant toxicity was not detected until the millimolar range
(NSC1000). Results shown are mean 6 SEM for n¼ 3 experiments.
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DISCUSSION
Understanding the mechanisms involved in fibroblast contrac-
tion is essential in order to establish the best therapeutic target
for the prevention of postoperative scarring in the filtering
bleb. We have shown previously that matrix remodeling by
MMPs plays an important part in tissue contraction, both in in
vitro14,15 and in ex vivo models,13 as well as in the rabbit model
of GFS.16,17 In addition, our recent work has shown that the
broad-spectrum MMP inhibitor, GM6001, also has a significant
effect on cell protrusive activity, which is one of the major
components of early matrix contraction.14,25 The inhibitor
affects both cell protrusive activity and direct collagen fiber
alignment by HTFs,14 suggesting that it interferes with signal
transduction pathways targeting actin dynamics.24
FIGURE 5. Knockdown of Rac1 in HTFs prevents collagen gel contraction (A) Rac1 SiRNA treatment led to a significant reduction in Rac1 protein
expression in HTFs, *P < 0.05. Shown is a representative Western blot and the corresponding quantitative protein analysis (mean 6 SEM, for n¼ 3
experiments). (B) Rac1 SiRNA treatment led to a 50% reduction in collagen gel contraction compared with SiRNA control pool. Results shown are
mean 6 SEM for n¼ 3 experiments, each carried out in triplicate.
FIGURE 6. Inhibition of small Rac1 or MMP activity prevents early cell protrusions, spreading, and fiber alignment. (A) Phase micrographs were
taken of HTFs in 3-D collagen gels 24 hours after treatment. Cells in the presence of FBS show distinct elongated fibroblast morphologies (arrow
heads). Following treatment with the MMP inhibitor GM6001 (FBSþGM, 100 lM) or the Rac inhibitor NSC23766 (FBSþNSC, 50 lM), cell
morphology is altered with rounder cell bodies and finer protrusions (arrows). Scale bar, 200 lm. (B) F-actin (rhodamine phalloidin) staining of
HTFs in collagen gels. A series of z-stacks was acquired in gels at 24 hours and merged to show a 2-D projection. Scale bar, 40 lm. (C) Confocal
reflection microscopy showing collagen fibers in gels at 24 hours. Cells in the presence of FBS show significant fiber alignment (arrow heads),
which is prevented in the presence of either the MMP inhibitor or the Rac1 inhibitor. Scale bar, 27 lm.
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The small GTPases of the Rho family are the main regulators
of the actin cytoskeleton22,24; and within this family, the small
GTPase Rac1 is thought to be a master regulator of cell
protrusive activity and motility.22,24,35 More recently, Rac1
expression has been associated with matrix remodeling in
fibroblasts, both in the context of tumor-promoting stroma,36
as well as fibrotic diseases.37 Indeed, fibroblasts expressing
constitutively active GTPases successfully contract collagen
matrices.38 Rac1 inhibition also reverses the elevated contrac-
tile phenotype of fibroblasts from patients who suffer from the
chronic fibrotic disease, scleroderma37 and alters the contrac-
tile and tumor-promoting properties of cancer-associated
fibroblasts.36 Furthermore, Rac1 depletion leads to delayed
wound healing in mice, with a significantly reduced contractile
and fibrotic phenotype.39 We demonstrate here that Rac1
inhibition dramatically reduces matrix contraction by Tenon’s
fibroblasts, as well as ex vivo tissue contraction, suggesting an
essential role for Rac1 in ocular scarring. Furthermore, we
show that transient treatment with the Rac1 inhibitor is
sufficient to prevent matrix remodeling and tissue contraction,
suggesting that it can permanently alter the contractile
properties of ocular fibroblasts, similar to its effect in dermal
fibroblasts.37
Although inhibition of Rac1 would dramatically alter cell
protrusive activity,22,24 this effect is likely to be limited to early
contraction, and we have shown that full matrix contraction is
linked to MMP-mediated collagen degradation and matrix
remodeling.14,25 Rather, Rac1 inhibition appears to trigger
changes in gene expression that prevents the cells from
expressing the fibrotic phenotype, therefore blocking their
ability to remodel the matrix. We show that while treatment
with the broad-spectrum MMP inhibitor does not reduce the
level of MMP expression, a single 24-hour exposure to the Rac1
inhibitor reduces expression of MMP1 after 3 days. While MMP
inhibitors have shown great promise in modulating tissue
contraction and scarring in various models,4,15–18 one of their
main drawbacks is that they can lead to a significant increase in
MMP expression, such as MT1-MMP in ocular and dermal
fibroblasts14,18 or MMP9 in cutaneous wounds.33,34 This could
lead to failure in preventing contraction in the long term33,34 if
active concentrations of MMP inhibitors are not maintained. By
contrast, we demonstrate here that a transient treatment with
the Rac1 inhibitor prevents matrix degradation and remodeling
as efficiently as continuous exposure to GM6001. However,
unlike treatment with GM6001, Rac1 inhibition results in a
significant long-term reduction in MMP1 expression in the later
stage of contraction and does not trigger a reactive overex-
pression of other major MMPs. At present, it is still unclear
how Rac1 regulates MMP expression, but a number of studies
have shown that Rac1 inhibition results in a decrease in MMP
expression, particularly MMP1,40–42 possibly through the
ERK41,43 or NFjB pathways.40,44 Further work will be needed
to identify the pathway at work in HTFs as well as the full array
of pro-fibrotic genes downstream of Rac1 activation.
In summary, this study shows for the first time that Rac1 is
an important component of Tenon’s capsule tissue contraction
and that transient treatment with the Rac1 inhibitor is
sufficient to prevent in vitro collagen matrix contraction,
FIGURE 7. Inhibition of Rac1 signaling prevents collagen matrix degradation by HTFs. HTF cells were cast in collagen gels in the presence of 10%
serum (FBS) and treated with GM6001 (GM, 100 lM) or NSC23766 (50 lM, first 24 hours only). (A) At day 7, the gels were stained with Coomassie
blue, and the absorbance of the extracted dye was measured at 550 nm to assess the total protein content, which correlates with collagen
concentration. Results shown are mean 6 SEM for n¼3 experiments. Significantly higher concentrations (***P < 0.001) in collagen are seen at day 7
following all treatments. (B) At day 7, confocal reflection microscopy was carried out to assess fiber integrity. Representative single z-sections were
captured for each treatment using a cell-free area. Reflection of fibers can clearly be seen following all treatments in comparison with a lack of fibers
in samples treated with FBS alone. Scale bar, 40 lm.
4688 Tovell et al. IOVS, July 2012, Vol. 53, No. 8
FIGURE 8. Inhibition of Rac1 signaling prevents matrix degradation in live segments of conjunctiva. Reflection microscopy of collagen fibers (red)
and living cells stained with the Vibrant CFDA Cell Tracer kit (green) were visualized with confocal microscopy. Shown are full 3-D reconstructions
of representative confocal z-stacks. In freshly isolated segments of porcine conjunctiva, thick collagen fibers can be seen (control, t¼ 0). After 28
days in the presence of 10% serum (FBS), most of the collagen fibers have been degraded; however, the cells remain fully viable. MMC treatment (0.5
mg/mL, for 2 minutes at the onset of assay) rescues the fiber degradation induced by FBS, although no viable cells can be found. Treatment with
NSC23766 (50 lM for 24 hours, once a week) also rescues fiber integrity without causing cell death. Scale bar, 90 lm.
FIGURE 9. Transient early inhibition of Rac1 leads to a long-term reduction in MMP1 expression. MMP1 expression was investigated in contracting
fibroblasts in collagen gels at days1, 3, 5, and 7, following treatment with GM6001 (100 lM continuous) or NSC23766 (50 lM, first 24 hours only).
(A) QRT-PCR results showing a significant reduction in MMP1 mRNA expression following transient treatment with NSC23766. Treatment with
GM6001 caused no reduction in MMP1 gene expression. HPRT1 mRNA levels were used to normalize samples for cell numbers and individual mRNA
levels are shown normalized to nontreated cells in freshly polymerized gels (t¼0). Significant differences are expressed as *P < 0.05, **P < 0.01, ***P
< 0.001. Results shown are mean 6 SEM for n ¼ 3 experiments. (B) Western blot analysis showing a reduction of MMP1 protein expression
following transient treatment with NSC23766 (n¼ 2, representative blot).
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intact tissue contraction, and matrix degradation and also to
reduce MMP1 expression, whilst showing no increase in
mRNA expression of other MMPs.
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